Amgen AMGN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Amgen to appeal rejection of bid to block Novartis biosimilar drug

      Headlines

      Wed, 25 Mar 2015

      SAN FRANCISCO, March 25 (Reuters) - Amgen Inc will appeal the rejection of its bid to block the sale of Novartis AG's biosimilar form of Neupogen, Amgen 's blockbuster drug used to prevent infections...

    2. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

      Headlines

      Mon, 23 Mar 2015

      biosimilars (through a partnership with Amgen AMGN ) remain attractive internally developed ..... Thanks to its partnership with Amgen , we think Actavis possesses strong ..... term.) Under its partnership with Amgen , Actavis has biosimilar versions

    3. UPDATE 2-U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen

      Headlines

      Thu, 19 Mar 2015

      NEW YORK, March 19 (Reuters) - A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen 's blockbuster drug used to prevent infections in cancer patients.

    4. BRIEF-Novartis says it, Amgen want expedited appellate review of Neupogen decision

      Headlines

      Thu, 19 Mar 2015

      March 19 (Reuters) - Novartis AG : * Says it, Amgen both agreed to seek expedited review by U.S. appeals

    5. BRIEF- Amgen plans appeal of court ruling that could pave way for Novartis biosimilar

      Headlines

      Thu, 19 Mar 2015

      March 19 (Reuters) - Amgen Inc : * Says plans to appeal U.S. court ruling that rejected its bid to block

    6. U.S. judge rejects Amgen injunction bid against Novartis Sandoz unit

      Headlines

      Thu, 19 Mar 2015

      SAN FRANCISCO, March 19 (Reuters) - A U.S. judge on Thursday denied Amgen Inc's bid for a preliminary injunction against Novartis AG's Sandoz unit over disputed biologic product filgrastim.

    7. From Barron’s, March 9, 2015 (Part 2)

      Commentary

      Sat, 7 Mar 2015

      owns 2.5%; pg 14]; Foot Locker [ FL ; pg 18]; small-cap Century Communities [ CCS ; pg 26]; new drugs in pipeline [ AMGN , NVS, VRTX ; pg 33]; maritime infrastructure [ Orient Overseas /316.hk; pg 33]; Whirlpool [ WHR ; the CEO spotlight

    8. UPDATE 2-Novartis wins approval for first U.S. biosimilar drug

      Headlines

      Fri, 6 Mar 2015

      * Amgen seeking to block biosimilar's launch (Adds Amgen comment)

    9. UPDATE 1- Amgen says Kyprolis doubles progression-free survival vs Velcade

      Headlines

      Sun, 1 Mar 2015

      March 1 (Reuters) - Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday.

    10. Amgen says Kyprolis doubles progression-free survival vs Velcade

      Headlines

      Sun, 1 Mar 2015

      March 1 (Reuters) - Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday.

    « Prev12345Next »
    Content Partners